GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

The Indian pharmaceutical market (IPM) registered a 6.1 per cent value growth in October 2024, with major therapies showing ...

GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...

Kennedy Jr. has his way, get ready for even more anti-pharma rhetoric and potential instability at the Food and Drug ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

In its Q3 results, GSK (GSK), the first to receive U.S. approval for an RSV ... Its rival Pfizer (PFE) agreed as the New York ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

GSK has announced that it will be expanding its immunology pipeline by acquiring a clinical-stage T cell-engager from ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...